NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Vaccine. 2020 Nov 25;38(50):7892-7896. doi: 10.1016/j.vaccine.2020.10.064. Epub 2020 Oct 23.

Abstract

There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective efficacy of a SARS-CoV-2 subunit vaccine (NVX-CoV2373) produced from the full-length SARS-CoV-2 spike (S) glycoprotein stabilized in the prefusion conformation. Cynomolgus macaques (Macaca fascicularis) immunized with NVX-CoV2373 and the saponin-based Matrix-M™ adjuvant induced anti-S antibody that was neutralizing and blocked binding to the human angiotensin-converting enzyme 2 (hACE2) receptor. Following intranasal and intratracheal challenge with SARS-CoV-2, immunized macaques were protected against upper and lower infection and pulmonary disease. These results support ongoing phase 1/2 clinical studies of the safety and immunogenicity of NVX-CoV2327 vaccine (NCT04368988).

Keywords: COVID-19; Matrix-M adjuvant; NVX-CoV2373 nanoparticles; Nonhuman primate; SARS-CoV-2; Spike glycoprotein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / pharmacology
  • Adolescent
  • Adult
  • Aged
  • Angiotensin-Converting Enzyme 2 / immunology
  • Angiotensin-Converting Enzyme 2 / metabolism
  • Animals
  • Antibodies, Neutralizing
  • COVID-19 / immunology
  • COVID-19 / prevention & control*
  • COVID-19 Vaccines / genetics
  • COVID-19 Vaccines / immunology
  • COVID-19 Vaccines / pharmacology*
  • Chlorocebus aethiops
  • Female
  • Humans
  • Immune Sera / drug effects
  • Immune Sera / immunology
  • Macaca fascicularis
  • Male
  • Middle Aged
  • SARS-CoV-2 / immunology*
  • Spike Glycoprotein, Coronavirus / genetics
  • Vaccines, Synthetic / immunology
  • Vaccines, Synthetic / pharmacology
  • Vero Cells
  • Viral Load
  • Young Adult

Substances

  • Adjuvants, Immunologic
  • Antibodies, Neutralizing
  • COVID-19 Vaccines
  • Immune Sera
  • Spike Glycoprotein, Coronavirus
  • Vaccines, Synthetic
  • recombinant SARS-CoV-2 vaccine NVX-cov2373
  • spike protein, SARS-CoV-2
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2

Associated data

  • ClinicalTrials.gov/NCT04368988